Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.61 |
| ▸ | SGK1 | O00141 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 3/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | PLCG1 | P19174 | 3/20 | 0.45 |
| ▸ | ITK | Q08881 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166436 | 0.87 | AXL (0.55) | CAMKK2SGK1KITRIPK1IGF1R | |
| SCHEMBL4171095 | 0.86 | CAMKK2 (0.71) | CAMKK2SGK1KITRIPK1IGF1R | |
| SCHEMBL3767898 | 0.83 | AXL (0.54) | CAMKK2SGK1KITRIPK1IGF1R | |
| SCHEMBL4171110 | 0.80 | CAMKK2 (0.73) | CAMKK2SGK1KITRIPK1IGF1R | |
| SCHEMBL14069150 | 0.79 | BTK (0.50) | SGK1KITBTKNTRK1PLCG1 | |
| SCHEMBL3766865 | 0.78 | CAMKK2 (1.00) | CAMKK2SGK1RIPK1IGF1RAXL | |
| SCHEMBL4171104 | 0.77 | CAMKK2 (0.69) | CAMKK2SGK1KITRIPK1IGF1R | |
| SCHEMBL4158761 | 0.76 | CDK8 (0.56) | KITBTKNTRK1ITK | |
| SCHEMBL3692347 | 0.76 | CAMKK2 (0.69) | CAMKK2SGK1KITRIPK1IGF1R | |
| SCHEMBL3772477 | 0.74 | CAMKK2 (0.77) | CAMKK2SGK1KITNTRK1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | claimed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | claimed |
| EP-1828180-A1 | 1H-PYRROLO[2,3-BETA]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | claimed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| EP-1828180-A1 | 1H-PYRROLO[2,3-BETA]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | CAMKK2 157/4885SGK1 1/4885KIT 1364/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | CAMKK2 125/4885SGK1 1/4885KIT 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.